Pathos AI
Healthcare AI
Drug discovery and development / precision oncology platform[1][3][4][7][16]
Series D
Pathos AI (Pathos AI, Inc.) is a private, AI-enabled, clinical‑stage biotechnology company focused on re‑engineering oncology drug development and precision medicine by combining large-scale multimodal oncology patient data, proprietary biological modeling, and advanced artificial intelligence to optimize patient selection, accelerate clinical trials, and co‑develop or license clinical‑stage therapeutics with biopharma partners.
Company Details
- Website
- pathos.com
- Headquarters
- Chicago, Illinois, USA[3][6][8][9]
- Founded
- 2022
- Funding
- $467M+ (approximately $102M through Series C by Oct 2024 plus $365M Series D in May 2025)[7][11][17]
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring